Article
The CpG island methylator phenotype: what's in a name?
Cancer research - 1 Oct 2013
Hughes Laura A E, Melotte Veerle, de Schrijver Joachim, de Maat Michiel, Smit Vincent T H B M, Bovée Judith V M G, French Pim J, van den Brandt Piet A, Schouten Leo J, de Meyer Tim, van Criekinge Wim, Ahuja Nita, Herman James G, Weijenberg Matty P, van Engeland Manon
Abstract excerpt
Although the CpG island methylator phenotype (CIMP) was first identified and has been most extensively studied in colorectal cancer, the term "CIMP" has been repeatedly used over the past decade to describe CpG island promoter methylation in other tumor types, including bladder, breast, endometrial, gastric, glioblastoma (gliomas), hepatocellular, lung, ovarian, pancreatic, renal cell, and prostate cancers, as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.